Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening.

Thomas C. Wright, Mark Schiffman, Diane Solomon, J. Thomas Cox, Francisco A Garcia, Sue Goldie, Kenneth D Hatch, Kenneth L. Noller, Nancy Roach, Carolyn Runowicz, Debbie Saslow

Research output: Contribution to journalArticle

415 Citations (Scopus)

Abstract

Human papillomavirus (HPV) DNA testing was recently approved by the Food and Drug Administration for use as an adjunct to cytology for cervical cancer screening. To help provide guidance to clinicians and patients when using HPV DNA testing as an adjunct to cervical cytology for screening, a workshop was cosponsored by the National Institutes of Health-National Cancer Institute, American Society of Colposcopy and Cervical Pathology (ASCCP), and American Cancer Society. Consensus was reached based on a literature review, expert opinion, and unpublished results from large ongoing screening studies. The conclusions of the workshop were that HPV DNA testing may be added to cervical cytology for screening in women aged 30 years or more. Women whose results are negative by both HPV DNA testing and cytology should not be rescreened before 3 years. Women whose results are negative by cytology, but are high-risk HPV DNA positive, are at a relatively low risk of having high-grade cervical neoplasia, and colposcopy should not be performed routinely in this setting. Instead, HPV DNA testing along with cervical cytology should be repeated in these women at 6 to 12 months. If test results of either are abnormal, colposcopy should then be performed. This guidance should assist clinicians in utilizing HPV DNA testing in an effective manner, while minimizing unnecessary evaluations and treatments.

Original languageEnglish (US)
Pages (from-to)304-309
Number of pages6
JournalObstetrics and Gynecology
Volume103
Issue number2
StatePublished - Feb 2004
Externally publishedYes

Fingerprint

Cell Biology
DNA
Colposcopy
Education
National Cancer Institute (U.S.)
National Institutes of Health (U.S.)
Expert Testimony
United States Food and Drug Administration
Early Detection of Cancer
Uterine Cervical Neoplasms
Pathology
Neoplasms

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Wright, T. C., Schiffman, M., Solomon, D., Cox, J. T., Garcia, F. A., Goldie, S., ... Saslow, D. (2004). Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstetrics and Gynecology, 103(2), 304-309.

Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. / Wright, Thomas C.; Schiffman, Mark; Solomon, Diane; Cox, J. Thomas; Garcia, Francisco A; Goldie, Sue; Hatch, Kenneth D; Noller, Kenneth L.; Roach, Nancy; Runowicz, Carolyn; Saslow, Debbie.

In: Obstetrics and Gynecology, Vol. 103, No. 2, 02.2004, p. 304-309.

Research output: Contribution to journalArticle

Wright, TC, Schiffman, M, Solomon, D, Cox, JT, Garcia, FA, Goldie, S, Hatch, KD, Noller, KL, Roach, N, Runowicz, C & Saslow, D 2004, 'Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening.', Obstetrics and Gynecology, vol. 103, no. 2, pp. 304-309.
Wright, Thomas C. ; Schiffman, Mark ; Solomon, Diane ; Cox, J. Thomas ; Garcia, Francisco A ; Goldie, Sue ; Hatch, Kenneth D ; Noller, Kenneth L. ; Roach, Nancy ; Runowicz, Carolyn ; Saslow, Debbie. / Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. In: Obstetrics and Gynecology. 2004 ; Vol. 103, No. 2. pp. 304-309.
@article{0865f27589be4883af89c9d6991abc42,
title = "Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening.",
abstract = "Human papillomavirus (HPV) DNA testing was recently approved by the Food and Drug Administration for use as an adjunct to cytology for cervical cancer screening. To help provide guidance to clinicians and patients when using HPV DNA testing as an adjunct to cervical cytology for screening, a workshop was cosponsored by the National Institutes of Health-National Cancer Institute, American Society of Colposcopy and Cervical Pathology (ASCCP), and American Cancer Society. Consensus was reached based on a literature review, expert opinion, and unpublished results from large ongoing screening studies. The conclusions of the workshop were that HPV DNA testing may be added to cervical cytology for screening in women aged 30 years or more. Women whose results are negative by both HPV DNA testing and cytology should not be rescreened before 3 years. Women whose results are negative by cytology, but are high-risk HPV DNA positive, are at a relatively low risk of having high-grade cervical neoplasia, and colposcopy should not be performed routinely in this setting. Instead, HPV DNA testing along with cervical cytology should be repeated in these women at 6 to 12 months. If test results of either are abnormal, colposcopy should then be performed. This guidance should assist clinicians in utilizing HPV DNA testing in an effective manner, while minimizing unnecessary evaluations and treatments.",
author = "Wright, {Thomas C.} and Mark Schiffman and Diane Solomon and Cox, {J. Thomas} and Garcia, {Francisco A} and Sue Goldie and Hatch, {Kenneth D} and Noller, {Kenneth L.} and Nancy Roach and Carolyn Runowicz and Debbie Saslow",
year = "2004",
month = "2",
language = "English (US)",
volume = "103",
pages = "304--309",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening.

AU - Wright, Thomas C.

AU - Schiffman, Mark

AU - Solomon, Diane

AU - Cox, J. Thomas

AU - Garcia, Francisco A

AU - Goldie, Sue

AU - Hatch, Kenneth D

AU - Noller, Kenneth L.

AU - Roach, Nancy

AU - Runowicz, Carolyn

AU - Saslow, Debbie

PY - 2004/2

Y1 - 2004/2

N2 - Human papillomavirus (HPV) DNA testing was recently approved by the Food and Drug Administration for use as an adjunct to cytology for cervical cancer screening. To help provide guidance to clinicians and patients when using HPV DNA testing as an adjunct to cervical cytology for screening, a workshop was cosponsored by the National Institutes of Health-National Cancer Institute, American Society of Colposcopy and Cervical Pathology (ASCCP), and American Cancer Society. Consensus was reached based on a literature review, expert opinion, and unpublished results from large ongoing screening studies. The conclusions of the workshop were that HPV DNA testing may be added to cervical cytology for screening in women aged 30 years or more. Women whose results are negative by both HPV DNA testing and cytology should not be rescreened before 3 years. Women whose results are negative by cytology, but are high-risk HPV DNA positive, are at a relatively low risk of having high-grade cervical neoplasia, and colposcopy should not be performed routinely in this setting. Instead, HPV DNA testing along with cervical cytology should be repeated in these women at 6 to 12 months. If test results of either are abnormal, colposcopy should then be performed. This guidance should assist clinicians in utilizing HPV DNA testing in an effective manner, while minimizing unnecessary evaluations and treatments.

AB - Human papillomavirus (HPV) DNA testing was recently approved by the Food and Drug Administration for use as an adjunct to cytology for cervical cancer screening. To help provide guidance to clinicians and patients when using HPV DNA testing as an adjunct to cervical cytology for screening, a workshop was cosponsored by the National Institutes of Health-National Cancer Institute, American Society of Colposcopy and Cervical Pathology (ASCCP), and American Cancer Society. Consensus was reached based on a literature review, expert opinion, and unpublished results from large ongoing screening studies. The conclusions of the workshop were that HPV DNA testing may be added to cervical cytology for screening in women aged 30 years or more. Women whose results are negative by both HPV DNA testing and cytology should not be rescreened before 3 years. Women whose results are negative by cytology, but are high-risk HPV DNA positive, are at a relatively low risk of having high-grade cervical neoplasia, and colposcopy should not be performed routinely in this setting. Instead, HPV DNA testing along with cervical cytology should be repeated in these women at 6 to 12 months. If test results of either are abnormal, colposcopy should then be performed. This guidance should assist clinicians in utilizing HPV DNA testing in an effective manner, while minimizing unnecessary evaluations and treatments.

UR - http://www.scopus.com/inward/record.url?scp=1442305204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1442305204&partnerID=8YFLogxK

M3 - Article

C2 - 14754700

AN - SCOPUS:1442305204

VL - 103

SP - 304

EP - 309

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 2

ER -